These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides. Palani A; Shapiro S; Clader JW; Greenlee WJ; Vice S; McCombie S; Cox K; Strizki J; Baroudy BM Bioorg Med Chem Lett; 2003 Feb; 13(4):709-12. PubMed ID: 12639564 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Kim D; Wang L; Caldwell CG; Chen P; Finke PE; Oates B; MacCoss M; Mills SG; Malkowitz L; Gould SL; DeMartino JA; Springer MS; Hazuda D; Miller M; Kessler J; Danzeisen R; Carver G; Carella A; Holmes K; Lineberger J; Schleif WA; Emini EA Bioorg Med Chem Lett; 2001 Dec; 11(24):3103-6. PubMed ID: 11720852 [TBL] [Abstract][Full Text] [Related]
13. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. McCombie SW; Tagat JR; Vice SF; Lin SI; Steensma R; Palani A; Neustadt BR; Baroudy BM; Strizki JM; Endres M; Cox K; Dan N; Chou CC Bioorg Med Chem Lett; 2003 Feb; 13(3):567-71. PubMed ID: 12565973 [TBL] [Abstract][Full Text] [Related]
14. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents. Li B; Jones ED; Zhou E; Chen L; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D Bioorg Med Chem Lett; 2010 Sep; 20(17):5334-6. PubMed ID: 20674358 [TBL] [Abstract][Full Text] [Related]
15. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity. Hale JJ; Budhu RJ; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano SJ; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini EA Bioorg Med Chem Lett; 2002 Oct; 12(20):2997-3000. PubMed ID: 12270192 [TBL] [Abstract][Full Text] [Related]
17. New piperazinyl polyazacyclophane scaffolds, libraries and biological activities. An H; Haly BD; Cook PD Bioorg Med Chem Lett; 1998 Sep; 8(17):2345-50. PubMed ID: 9873539 [TBL] [Abstract][Full Text] [Related]
18. FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. Kim JT; Hamilton AD; Bailey CM; Domaoal RA; Wang L; Anderson KS; Jorgensen WL J Am Chem Soc; 2006 Dec; 128(48):15372-3. PubMed ID: 17131993 [TBL] [Abstract][Full Text] [Related]
19. New conformationally locked bicyclic N,O-nucleoside analogues of antiviral drugs. Procopio A; Alcaro S; De Nino A; Maiuolo L; Ortuso F; Sindona G Bioorg Med Chem Lett; 2005 Feb; 15(3):545-50. PubMed ID: 15664810 [TBL] [Abstract][Full Text] [Related]
20. Anti-AIDS agents. Part 47: Synthesis and anti-HIV activity of 3-substituted 3',4'-Di-O-(S)-camphanoyl-(3'R,4'R)-(+)-cis-khellactone derivatives. Xie L; Allaway G; Wild C; Kilgore N; Lee KH Bioorg Med Chem Lett; 2001 Sep; 11(17):2291-3. PubMed ID: 11527717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]